1/53
Comprehensive vocabulary flashcards covering classifications, clinical presentations, biochemical markers, diagnostic pathways, and treatments for inborn errors of metabolism.
Disorders of intoxication
The most common category of inborn errors of metabolism (including amino acid disorders, UCDs, organic acidemias, carbs, and purine/pyrimidine), characterized by accumulation of toxic substrates, treatable nature, nondysmorphic features, and the need to reduce toxic substrates.
Disorders of complex molecules
A category of inborn errors of metabolism (including LSDs, peroxisomal disorders, CDGs, cholesterol, and steroids) characterized by deposition of byproducts around the body (storage disorders), often progressive or later-onset course, and potential dysmorphic features.
Disorders of energy metabolism
A category of metabolic disorders (including carbs, fatty acids, and mitochondria) characterized by product deficiency, nondysmorphic features, signs of running out of energy, and potential acute presentation in infants.
Enzyme therapy for LSDs
Treatment that replaces an enzyme that is missing or not working, providing a functional version to break down accumulated substances, reduce cellular damage, and improve organ function.
Chaperone therapy
Oral medication consisting of small molecules that bind to remaining or faulty enzymes to assist proper folding and improve residual enzyme function (requiring residual enzymes to work).
X-linked metabolic conditions
Two classic examples of metabolic conditions inherited in an X-linked pattern are Fabry disease and Ornithine Transcarbamylase (OTC) deficiency.
Branched-chain amino acids
Valine, leucine, and isoleucine; leucine is specifically neurotoxic.
MCAD deficiency
A fatty acid oxidation disorder that was thought to account for 5–10% of SIDS cases before newborn screening began, and the initial target of expanded newborn screening using tandem mass spectrometry.
Mitochondrial inheritance types
Mitochondrial diseases can be inherited through autosomal recessive (AR), mitochondrial DNA (mtDNA), or X-linked patterns.
Ornithine transcarbamylase (OTC) deficiency
The most common urea cycle disorder; 50% of carrier females feel unable to perform driving because elevated ammonia levels can mimic driving under the influence, and male infants with severe classic disease can receive a liver transplant as a cure.
Very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency
The fatty acid oxidation disorder that takes the longest to resolve biochemically and molecularly after an abnormal newborn screen because the test is very sensitive, symptomatic individuals can have normal results, and patients need to be under metabolic stress.
C3 acylcarnitine elevation
An analyte elevation seen on newborn screening and acylcarnitine profiles that is indicative of propionic acidemia (PA) or methylmalonic acidemia (MMA).
Duarte galactosemia
A type of galactosemia that is common but clinically benign.
L-carnitine supplementation
An oral medication useful for the daily management and treatment of most patients with fatty acid oxidation disorders (FAODs).
Amino acid disorders
Metabolic conditions caused by an underlying defect in the metabolism of protein.
Mitochondrial disease organ involvement
Mitochondrial diseases impact organ systems with high energy demands, specifically the brain (CNS), heart, eyes, and muscle.
Tyrosinemia type 1
An amino acid disorder that clinically presents with liver dysfunction and produces the pathognomonic analyte succinylacetone in the urine.
Succinylacetone
A pathognomonic urine analyte diagnostic for tyrosinemia type 1.
Homocystinuria
An amino acid disorder that causes physical features similar to those seen in patients with Marfan syndrome.
Maternal PKU syndrome
A condition where infants born to mothers with PKU are born unhealthy with intellectual disability due to maternal failure to break down phenylalanine, resulting in 1.5 times elevated phenylalanine in the placenta, whereas infants with PKU born to carrier mothers are healthy at birth because maternal metabolism clears phenylalanine for them.
Glutaric acidemia type 1
An organic acidemia that causes a significantly increased risk for stroke.
Organic acidemias (MMA and PA)
Disorders such as methylmalonic acidemia and propionic acidemia that can cause metabolic acidosis and hyperammonemia, lead to eventual kidney failure, show elevated C3 levels, and can be successfully treated with liver transplantation.
MMA vs. PA management
Vitamin B12 supplementation is not optional in MMA, whereas biotin supplementation is optional in PA; MMA has multiple subtypes, whereas PA has only one subtype.
Urea cycle disorders (UCDs)
Inborn errors of metabolism whose primary clinical symptom is hyperammonemia.
Argininemia
A urea cycle defect whose primary presenting symptom is seizures.
Fatty acid beta-oxidation cycle
A metabolic pathway that shortens fatty acid chains by 2 carbon lengths with each turn of the cycle.
Aerobic respiration
A slower metabolic pathway requiring oxygen that occurs in the cytosol and then the mitochondria, converting pyruvate to acetyl-CoA through the TCA cycle and oxidative phosphorylation to produce ATP, CO2, and H2O.
Anaerobic respiration
A quick, oxygen-independent process occurring in the cytosol that yields only 2 ATP by breaking pyruvate into lactic acid and CO2.
Heteroplasmy
The coexistence of normal and abnormal mtDNA in varying proportions from person to person, tissue to tissue, and cell to cell, requiring a specific proportion (threshold effect) to manifest symptoms.
Glycogen storage disease (GSD)
A group of carbohydrate disorders primarily impacting the liver that present with chubby cheeks and carry a constant threat of hypoglycemia, requiring frequent feeding.
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
The most common enzyme deficiency in the world, presenting clinically with hemolytic anemia in male infants.
Congenital disorders of glycosylation (CDGs)
Disorders involving glycosylation pathways with approximately 400 implicated genes (only 200 currently identified), which makes genome sequencing recommended when panel or exome sequencing is negative.
ERT vs. PCT
Enzyme replacement therapy (ERT) is administered intravenously and cannot usually cross the blood-brain barrier, while pharmacological chaperone therapy (PCT) is administered orally, can cross the blood-brain barrier, and requires residual enzymes.
Eye of the tiger sign
A specific brain MRI finding seen in disorders characterized by iron accumulation in the brain.
Orotic acid
A pathognomonic urine analyte found elevated in certain patients with urea cycle defects.
Autosomal recessive (AR)
The most common mode of inheritance among biochemical genetic disorders.
Gaucher disease
The first lysosomal storage disorder to have an FDA-approved treatment.
C26 (Hexacosanoic acid)
The primary analyte measured on newborn screening to detect X-linked adrenoleukodystrophy (X-ALD) and Zellweger spectrum disorders.
Menkes disease vs. Wilson disease
Disorders of copper metabolism characterized by systemic copper deficiency in Menkes disease versus copper overload/accumulation in Wilson disease.
Fetal vs. Adult hemoglobin composition
Fetal hemoglobin (HbF) consists of 2 gamma and 2 alpha globin chains (α2γ2), whereas adult hemoglobin (HbA) consists of 2 beta and 2 alpha globin chains (α2β2).
Hemoglobin Bart
A condition with no functional alpha globin chains, forming a tetramer of 4 gamma chains (γ4) that is incompatible with life.
MPS I vs. MPS II
Both mucopolysaccharidoses cause hepatomegaly and elevated dermatan sulfate (DS) and heparan sulfate (HS) GAGs in urine; MPS I is autosomal recessive with corneal clouding, while MPS II is X-linked without corneal clouding.
Pyridoxine-dependent epilepsy
A specific type of epilepsy that is treatable with vitamin B6 (pyridoxine) supplementation.
Congenital adrenal hyperplasia (CAH)
An inborn error affecting steroid hormone synthesis, specifically impacting cortisol, aldosterone, and androgen precursors.
Paired blood-to-CSF metabolite ratio testing
A diagnostic method evaluating metabolite ratios between paired blood and cerebrospinal fluid to diagnose GLUT1 deficiency and nonketotic hyperglycinemia (NKH).
Primary biochemical genetic screening tests
The three standard biochemical screens: plasma amino acids, urine organic acids, and plasma acylcarnitine profile.
Smith-Lemli-Opitz (SMO) syndrome
A metabolic disorder characterized by 2,3 syndactyly, autism, and congenital heart defects; features can be clinically mimicked by prenatal fentanyl exposure.
Alpha thalassemia cis vs. trans deletions
The genetic configuration of alpha-globin deletions, where deletions on the same chromosome (cis) are most prevalent in Asian populations and deletions on opposite chromosomes (trans) are most prevalent in African populations.
X-linked adrenoleukodystrophy (X-ALD)
The most common peroxisomal disorder, primarily affecting the adrenal glands and brain, diagnosed via very long-chain fatty acids (VLCFA), and treatable with HSCT or gene therapy initiated at or before the onset of leukodystrophy.
CRIM status
Cross-reactive immunologic material status, which is essential to assess prior to initiating enzyme replacement therapy in Pompe disease.
Zellweger syndrome
A severe peroxisomal disorder presenting in newborns with severe hypotonia, liver and kidney disease, and a large anterior fontanel.
Fabry disease
An X-linked lysosomal storage disorder characteristically presenting with severe hand and foot pain (acroparesthesias).
Acute intermittent porphyria (AIP)
An acute hepatic porphyria typically presenting in women aged 18–39 years with acute abdominal pain, dark-colored urine, headaches, and psychiatric symptoms.
Catabolism
The state of metabolic breakdown during which patients with inborn errors of metabolism typically become acutely ill.